PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Lynparza in combination with abiraterone granted priority review in US

A new therapy is aimed at patients with metastatic castration-resistant prostate cancer. AstraZeneca’s supplemental new drug application for Lynparza (olaparib) i...
Continue Reading →
News

Merck jumps back into Alzheimer’s waters with Cerevance pact

Merck (MSD) has inked a multi-year strategic research collaboration with Massachusetts-based Cerevance, marking Merck's biggest move in the ...
Continue Reading →
News

MacroGenics to cut workforce, close satellite sites

MacroGenics has initiated cost-saving measures through a corporate restructuring, announcing job cuts and the closure of two satellite facilities. The planne...
Continue Reading →
News

AstraZeneca, Daiichi Sankyo grab first FDA approval for targeted HER2-low breast cancer drug

The U.S. FDA has approved the first targeted therapy for patients with HER2-low breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu. Enhertu is now ...
Continue Reading →
News

SyneuRx reveals results of COVID-19 candidate trial

Positive data show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19. SyneuRx – a company focused on the development of drugs for COVI...
Continue Reading →
News

EQRx announces further results from phase 3 trial of sugemalimab

The study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer. EQRx has announced a late-breaking oral presentation of update...
Continue Reading →
News

Neil Jones is appointed as the new Chief Commercial Officer (CCO) of Aenova Group

Neil Jones has been the new Chief Commercial Officer (CCO) of Aenova Group since July 18, 2022. As a member of the Executive Leadership Team (ELT), he will play ...
Continue Reading →
News

Cyclerion reveals data for schizophrenia therapy

Study data demonstrate the positive effects of CY6463 on cognition and inflammation. Cyclerion Therapeutics has announced positive top-line data from its clinical...
Continue Reading →
News

Tallac announces first patient treated with TAC-001

The phase 1/2 study is for patients with advanced or metastatic solid tumours. Tallac Therapeutics has announced that the first patient has been treated with TAC-...
Continue Reading →
News

Scientists to rewrite DNA in search for heart disease cure

The British Heart Foundation’s ‘Big Beat Challenge’ grant of £30m for research into cardiovascular medicine was given to CureHeart. An injectable cure for inherit...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026